Eisai and Biogen's Alzheimer's Drug Application Receives FDA Priority Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: NASDAQ.COM
- FDA Priority Review: Eisai's Supplemental Biologics License Application (sBLA) has been accepted by the FDA, with a decision expected by May 24, 2026, potentially providing early Alzheimer's patients with a weekly self-injection dosage, significantly enhancing medication convenience.
- Clinical Data Support: The sBLA is backed by data from the Phase 3 Clarity AD study, which demonstrated that a weekly 500 mg subcutaneous injection achieves similar clinical and biomarker benefits as the bi-weekly intravenous administration, indicating the new formulation's efficacy and safety.
- Significant Market Potential: The global Alzheimer's therapeutics market is projected to reach $15.19 billion by 2030, growing at a CAGR of 19.99%, positioning the Eisai-Biogen collaboration to capture a substantial share in this rapidly expanding market.
- Enhanced Injection Convenience: The LEQEMBI IQLIK autoinjector has an injection time of approximately 15 seconds per dose, which may reduce healthcare resource consumption associated with intravenous dosing, such as infusion preparation and nurse monitoring, thereby improving patient adherence to treatment.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
25 Analyst Rating
11 Buy
13 Hold
1 Sell
Moderate Buy
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
